125 related articles for article (PubMed ID: 8422593)
21. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: a Gynecologic Oncology Group Study.
Omura GA; Bundy BN; Berek JS; Curry S; Delgado G; Mortel R
J Clin Oncol; 1989 Apr; 7(4):457-65. PubMed ID: 2926470
[TBL] [Abstract][Full Text] [Related]
22. High-dose platinum versus standard dose in advanced ovarian carcinoma: a randomized trial from the Gynecologic Cooperative Group of the French Comprehensive Cancer Centers (FNCLCC).
Joly F; Héron JF; Kerbrat P; Chauvergne J; Rios M; Mayer F; Chinet-Charrot P; Goupil A; Lebrun-Jezekova D; Vennin D; Lhommé C; Macé-Lesec'h J; Crouet H
Gynecol Oncol; 2000 Sep; 78(3 Pt 1):361-8. PubMed ID: 10985895
[TBL] [Abstract][Full Text] [Related]
23. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
24. Randomized comparison of cisplatin plus epirubicin or doxorubicin for advanced epithelial ovarian carcinoma. A multicenter trial.
Homesley HD; Harry DS; O'Toole RV; Hoogstraten B; Franklin EW; Cavanagh D; Nahhas WA; Smith JJ; Lovelace JV
Am J Clin Oncol; 1992 Apr; 15(2):129-34. PubMed ID: 1553900
[TBL] [Abstract][Full Text] [Related]
25. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study.
Omura G; Blessing JA; Ehrlich CE; Miller A; Yordan E; Creasman WT; Homesley HD
Cancer; 1986 May; 57(9):1725-30. PubMed ID: 3513943
[TBL] [Abstract][Full Text] [Related]
26. Combination chemotherapy with epirubicin and cisplatin in ovarian carcinoma.
Fuith LC; Bazzanella A; Hetzel H
Arch Gynecol Obstet; 1988; 244(1):15-21. PubMed ID: 3240002
[TBL] [Abstract][Full Text] [Related]
27. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer.
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
N Engl J Med; 1996 Jan; 334(1):1-6. PubMed ID: 7494563
[TBL] [Abstract][Full Text] [Related]
28. Chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide as an adjunct to surgery in stage Ic-II epithelial ovarian carcinoma. Gynecologic Oncology Group of the Comprehensive Cancer Center.
Wils J; van Geuns H
Am J Clin Oncol; 1989 Jun; 12(3):251-4. PubMed ID: 2658540
[TBL] [Abstract][Full Text] [Related]
29. Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration.
Hainsworth JD; Grosh WW; Burnett LS; Jones HW; Wolff SN; Greco FA
Ann Intern Med; 1988 Feb; 108(2):165-70. PubMed ID: 3124679
[TBL] [Abstract][Full Text] [Related]
30. Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma.
Louie KG; Ozols RF; Myers CE; Ostchega Y; Jenkins J; Howser D; Young RC
J Clin Oncol; 1986 Nov; 4(11):1579-85. PubMed ID: 3095501
[TBL] [Abstract][Full Text] [Related]
31. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma.
Wils J; Blijham G; Naus A; Belder C; Boschma F; Bron H; Ceelen T; Eekhout A; von Erp J; Geelen P
J Clin Oncol; 1986 Jul; 4(7):1068-73. PubMed ID: 3723166
[TBL] [Abstract][Full Text] [Related]
32. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
33. Weekly cisplatin given for 2 months versus cisplatin plus cyclophosphamide given for 5 months after cytoreductive surgery for advanced ovarian cancer.
Bolis G; Favalli G; Danese S; Zanaboni F; Mangili G; Scarabelli C; Tateo S; Valsecchi MG; Scarfone G; Richiardi G; Frigerio L; Melpignano M; Villa A; Parazzini F
J Clin Oncol; 1997 May; 15(5):1938-44. PubMed ID: 9164205
[TBL] [Abstract][Full Text] [Related]
34. Cisplatin and cyclophosphamide in advanced ovarian carcinoma: activity and toxicity of an ambulatory regimen.
Zambetti M; Gianni L; Di Re F; Spatti G; Fontanelli R; Escobedo A; De Palo G; Bonadonna G
Am J Clin Oncol; 1990 Jun; 13(3):199-203. PubMed ID: 2161174
[TBL] [Abstract][Full Text] [Related]
35. Addition of epirubicin to conventional chemotherapy in patients with advanced ovarian cancer: sequential therapy -a retrospective evaluation.
Özgül N; Köse MF; Keskin HL; Turan AT; Karalök MA; Üreyen I; Borani N; Tulunay HG
Turk J Med Sci; 2014; 44(2):212-9. PubMed ID: 25536727
[TBL] [Abstract][Full Text] [Related]
36. Combination of chemotherapy and recombinant alpha-interferon in advanced non-small cell lung cancer. Multicentric Randomized FONICAP Trial Report. The Italian Lung Cancer Task Force.
Ardizzoni A; Salvati F; Rosso R; Bruzzi P; Rubagotti A; Pennucci MC; Mariani GL; De Marinis F; Pallotta G; Antilli A
Cancer; 1993 Nov; 72(10):2929-35. PubMed ID: 8221559
[TBL] [Abstract][Full Text] [Related]
37. Treatment of advanced epithelial ovarian cancer with cisplatin and cyclophosphamide.
Gershenson DM; Wharton JT; Copeland LJ; Stringer CA; Edwards CL; Kavanagh JJ; Freedman RS
Gynecol Oncol; 1989 Mar; 32(3):336-41. PubMed ID: 2920954
[TBL] [Abstract][Full Text] [Related]
38. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
39. Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer.
Kaye SB; Lewis CR; Paul J; Duncan ID; Gordon HK; Kitchener HC; Cruickshank DJ; Atkinson RJ; Soukop M; Rankin EM
Lancet; 1992 Aug; 340(8815):329-33. PubMed ID: 1353804
[TBL] [Abstract][Full Text] [Related]
40. The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP).
Hainsworth JD; Jones HW; Burnett LS; Johnson DH; Greco FA
Am J Clin Oncol; 1990 Oct; 13(5):410-5. PubMed ID: 2121019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
